Breaking News Instant updates and real-time market news.

AMRN

Amarin

$3.10

-0.06 (-1.90%)

05:44
04/12/18
04/12
05:44
04/12/18
05:44

Amarin presents two posters about Vascepa at the National Kidney Foundation

Amarin announced the presentation of two posters this week at the National Kidney Foundation 2018 Spring Clinical Meetings in Austin, TX, April 10-14, 2018. These analyses highlight the need for further research in patients with reduced kidney function in conjunction with diabetes mellitus or ongoing inflammation, as denoted by elevated high sensitivity C-reactive protein, or hsCRP, levels, and persistent high triglycerides, or TG, despite statin therapy due to the association with increased cardiovascular disease, or CVD, risk. The poster titled "Icosapent Ethyl Reduces Potentially Atherogenic Lipid and Inflammatory Markers in High-Risk Statin-Treated Patients With Persistent High Triglycerides, eGFR less than90 mL/min/1.73 m2, and Diabetes Mellitus" showed that, consistent with overall ANCHOR study results, compared with placebo, icosapent ethyl, or IPE, 4g/day significantly decreased the primary endpoint of triglycerides, or TG, and other lipids without increasing LDL-C. Apolipoproteins and markers of oxidation and inflammation were significantly improved.

AMRN Amarin
$3.10

-0.06 (-1.90%)

04/09/18
JEFF
04/09/18
NO CHANGE
Target $7
JEFF
Buy
Amarin risk/reward favorable into Q3 data, says Jefferies
Jefferies analyst Matthew Andrews surveyed 50 U.S. physicians and high prescribers of Amarin's Vascepa to assess current use of Vascepa in mixed dyslipidemia and severe high triglycerides, and future prescribing habits based on the REDUCE-IT data. The survey indicates Vascepa is the leading triglycerides-lowering drug in severe hypertriglyceridemia and mixed dyslipidemia, and positive MACE data in the REDUCE-IT trial could increase use 125% and 50%, respectively, Andrews tells investors in a research note. The analyst estimates peak-adjusted U.S. Vascepa sales of $1.06B by 2030. He sees a favorable risk/reward on Amarin shares into the Q3 data. The stock has upside to $7 on positive data and downside to $2.25 on a negative readout, Andrews contends. He keeps a Buy rating on Amarin with a $7 price target.
03/01/18
HCWC
03/01/18
NO CHANGE
Target $10
HCWC
Buy
Amarin has 'significant upside' on positive trial data, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein continues to believe that Amarin's current valuation is supported by Vascepa sales alone. The potential success of the Reduce-It trial represents "significant upside," Fein tells investors in a research note. He reiterates a Buy rating on Amarin with a $10 price target following the company's Q4 results.
02/20/18
CANT
02/20/18
NO CHANGE
Target $10
CANT
Overweight
Amarin shares compelling ahead of data, Cantor Fitzgerald
Amarin shares represent a "compelling investment opportunity" ahead of data for the company's Reduce-It study before the end of Q3, Cantor Fitzgerald analyst Louise Chen wrote Friday in a research note to investors. She expects the data to be positive. Amarin recently raised $70M and could raise up to another $10.5M gross, if overallotment is exercised, ahead of the data readout which removes a financing overhang and accelerates the company's plan to expand its sales and promotion of Vascepa, Chen argues. She keeps an Overweight rating on the shares with a $10 price target.
01/23/18
CANT
01/23/18
NO CHANGE
Target $10
CANT
Overweight
Amarin shares have room to run ahead of data, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen views this morning's announcement from Amarin as good news since the company is on track to report top-line results from the study before the end of Q3. Amarin this morning announced that its Reduce-It cardiovascular outcomes study has reported and documented more than 90% of the targeted 1,612 primary major adverse cardiovascular events. The analyst believes the shares have to room to run ahead of the data release. She keeps an Overweight rating on the name with a $10 price target.

TODAY'S FREE FLY STORIES

JD

JD.com

$35.84

-0.03 (-0.08%)

13:50
04/25/18
04/25
13:50
04/25/18
13:50
Options
Volatility play in JD as January puts trade in large blocks Wednesday »

Volatility play in JD as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:50
04/25/18
04/25
13:50
04/25/18
13:50
General news
Treasury Curve Action: steepeners resumed »

Treasury Curve Action:…

AMD

AMD

$9.69

-0.4 (-3.96%)

13:40
04/25/18
04/25
13:40
04/25/18
13:40
Options
Aggresive buyer lays out $2.2M for deep in the money Advanced Micro puts »

Aggresive buyer lays out…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 02

    May

AAPL

Apple

$164.70

1.83 (1.12%)

13:40
04/25/18
04/25
13:40
04/25/18
13:40
Conference/Events
President Trump to meet with Apple CEO Cook »

The meeting between…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 01

    May

WELL

Welltower

$49.86

-1.16 (-2.27%)

, QCP

Quality Care Properties

$21.35

0.55 (2.64%)

13:37
04/25/18
04/25
13:37
04/25/18
13:37
Periodicals
Promedica, Welltower offering $2B to aquire Quality Care Properties, Reuters says »

Promedica and Welltower…

WELL

Welltower

$49.86

-1.16 (-2.27%)

QCP

Quality Care Properties

$21.35

0.55 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 03

    May

  • 04

    May

EBAY

eBay

$40.63

-0.55 (-1.34%)

13:36
04/25/18
04/25
13:36
04/25/18
13:36
Technical Analysis
Technical Earnings Preview: eBay in uptrend ahead of earnings »

The shares have been in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LC

LendingClub

$2.78

-0.485 (-14.85%)

13:36
04/25/18
04/25
13:36
04/25/18
13:36
Hot Stocks
LendingClub calls charges in FTC complaint 'legally and factually unwarranted' »

Following an inquiry that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

LC

LendingClub

$2.78

-0.485 (-14.85%)

13:36
04/25/18
04/25
13:36
04/25/18
13:36
Hot Stocks
Breaking Hot Stocks news story on LendingClub »

LendingClub calls charges…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

FB

Facebook

$160.15

0.49 (0.31%)

, GOOG

Alphabet

$1,021.04

1.58 (0.15%)

13:35
04/25/18
04/25
13:35
04/25/18
13:35
Periodicals
Facebook declines to testify at U.S. House hearing on social media, Reuters says »

A Facebook (FB) spokesman…

FB

Facebook

$160.15

0.49 (0.31%)

GOOG

Alphabet

$1,021.04

1.58 (0.15%)

GOOGL

Alphabet Class A

$1,023.95

0.97 (0.09%)

TWTR

Twitter

$28.98

-1.5 (-4.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 30

    May

  • 27

    Jul

HOG

Harley-Davidson

$41.88

-0.13 (-0.31%)

13:30
04/25/18
04/25
13:30
04/25/18
13:30
Options
Hefty spread opened in Harley Davidson options »

Hefty spread opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

TWTR

Twitter

$28.97

-1.51 (-4.95%)

13:29
04/25/18
04/25
13:29
04/25/18
13:29
Recommendations
Twitter analyst commentary  »

Twitter outlook looks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    May

  • 27

    Jul

XOM

Exxon Mobil

$78.56

0.21 (0.27%)

13:29
04/25/18
04/25
13:29
04/25/18
13:29
Hot Stocks
Exxon Mobil boosts Q2 dividend to 82c from 77c »

Exxon Mobil's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

FB

Facebook

$160.04

0.38 (0.24%)

13:25
04/25/18
04/25
13:25
04/25/18
13:25
Technical Analysis
Technical Earnings Preview: Facebook in an active bearish pattern before news »

There is a bearish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

MGM

MGM Resorts

$35.36

-0.16 (-0.45%)

13:25
04/25/18
04/25
13:25
04/25/18
13:25
Options
MGM Resorts call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

CBLK

Carbon Black

13:25
04/25/18
04/25
13:25
04/25/18
13:25
Conference/Events
Cowen software analyst to hold an analyst/industry conference call »

Infrastructure &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

BA

Boeing

$338.10

9.1 (2.77%)

13:23
04/25/18
04/25
13:23
04/25/18
13:23
Upgrade
Boeing rating change  »

Boeing upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    May

13:20
04/25/18
04/25
13:20
04/25/18
13:20
General news
Treasury Action: the OK auction hasn't really registered on Treasury screens »

Treasury Action: the OK…

TER

Teradyne

$35.36

-6.14 (-14.80%)

, AAPL

Apple

$165.05

2.18 (1.34%)

13:18
04/25/18
04/25
13:18
04/25/18
13:18
Recommendations
Teradyne, Apple analyst commentary  »

Teradyne valuation…

TER

Teradyne

$35.36

-6.14 (-14.80%)

AAPL

Apple

$165.05

2.18 (1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 01

    May

  • 16

    May

  • 30

    May

$NSD

NASDAQ Market Internals

13:17
04/25/18
04/25
13:17
04/25/18
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
04/25/18
04/25
13:16
04/25/18
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCP

Quality Care Properties

$20.71

-0.09 (-0.43%)

, WELL

Welltower

$50.33

-0.69 (-1.35%)

13:15
04/25/18
04/25
13:15
04/25/18
13:15
Periodicals
Promedica, Welltower offering $2B to buy Quality Care Properties, Reuters says »

The $2B bid from…

QCP

Quality Care Properties

$20.71

-0.09 (-0.43%)

WELL

Welltower

$50.33

-0.69 (-1.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 03

    May

  • 04

    May

13:15
04/25/18
04/25
13:15
04/25/18
13:15
General news
Treasury's $35 B 5-year auction a little better than average »

Treasury's $35 B…

QCOM

Qualcomm

$49.62

-0.32 (-0.64%)

, AVGO

Broadcom

$228.00

-0.25 (-0.11%)

13:14
04/25/18
04/25
13:14
04/25/18
13:14
Earnings
On The Fly: What to watch in Qualcomm's earnings report »

Qualcomm (QCOM) is…

QCOM

Qualcomm

$49.62

-0.32 (-0.64%)

AVGO

Broadcom

$228.00

-0.25 (-0.11%)

SFTBF

SoftBank

NXPI

NXP Semiconductors

$101.89

0.12 (0.12%)

ZTCOY

ZTE Corp.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

LOW

Lowe's

$81.88

-1.02 (-1.23%)

13:10
04/25/18
04/25
13:10
04/25/18
13:10
Options
Notable spread opened in Lowes as shares fall further »

Notable spread opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTLA

Portola Pharmaceuticals

$33.73

-0.9 (-2.60%)

13:09
04/25/18
04/25
13:09
04/25/18
13:09
Hot Stocks
Portola to present new interim Phase 2 data for cerdulatinib at ASCO »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 21

    May

  • 12

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.